Aoxiang Pharmaceutical recently announced that the company's wholly-owned subsidiary Aoxiang Hong Kong company and Yingpai Pharmaceutical company in2020years11month27A Share Subscription Agreement was signed on January 1, 2007. Aoxiang Hong Kong Company will contribute200$10,000. Owned by British School of Pharmaceuticals1%Equity. Aoxiang Pharmaceutical is not only the first pharmaceutical enterprise with academician workstation among Taizhou medical and chemical enterprises, but also a high-tech enterprise. At present, the company has built excellent platforms such as Zhejiang Provincial Research Institute, provincial Enterprise Technology Center, provincial academician expert workstation and provincial postdoctoral workstation. Current employee800People, have a doctor, master, etc200Multi-member research and development and analysis team, through Aoxiang Hong Kong company equity subscription, is conducive to the strategic layout of the company.

Ringser's view:The acquisition of Yingpai Pharmaceutical by Aoxiang Pharmaceutical is mainly to meet the long-term business development needs of the company in overseas markets in the future, further expand the pharmaceutical industry layout, achieve the company's strategic development objectives and enhance the company's sustainable competitiveness. The acquisition through the Hong Kong subsidiary is because the transfer of shares between Hong Kong companies is easier and more convenient, and the follow-up is easier to manage.

CycloseThe company focuses on providing corporate audit, tax declaration, registration, annual inspection, tax planning and other services in Hong Kong, Singapore, Dubai and other regions. Efficient, rigorous, intimate service has been favored by many private enterprises, listed companies and large state-owned enterprises.